Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)
NCT05114096 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3254
Last updated 2026-01-07
Summary
Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome.
The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity.
The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.
Conditions
- Preterm Birth
- Premature Birth
- Complication of Prematurity
- Obstetric Labor, Premature
- Pregnancy Complications
Interventions
- DRUG
-
Celestone + placebo
After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.
- DRUG
-
Celestone + Celestone
After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.
Sponsors & Collaborators
-
Hamilton Health Sciences Corporation
collaborator OTHER -
Sunnybrook Research Institute
collaborator OTHER -
Women's and Children's Hospital, Australia
collaborator OTHER_GOV -
Canadian Institutes of Health Research (CIHR)
collaborator OTHER_GOV -
Medical Research Future Fund
collaborator OTHER -
University of Adelaide
collaborator OTHER - lead OTHER
Principal Investigators
-
Sarah D McDonald, MD,MSc,FRCSC · McMaster University
-
Kellie Murphy, MD,MSc,FRCSC · University of Toronto
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-20
- Primary Completion
- 2026-12-31
- Completion
- 2029-12-31
Countries
- Canada
Study Locations
More Related Trials
-
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery
NCT00004778 ·Status: COMPLETED ·Phase: PHASE3
-
Repeat Antenatal Corticosteroids
NCT03133104 ·Status: COMPLETED
-
Effect of Antenatal Corticosteroids on Neonatal Morbidity.
NCT03446937 ·Status: COMPLETED ·Phase: NA
-
Antenatal Betamethasone Compared to Dexamethasone - "BETACODE TRIAL"
NCT00418353 ·Status: COMPLETED ·Phase: NA
-
Maternal and Fetal/Neonatal Pharmacokinetics and - Dynamics of Corticosteroids During Pregnancy
NCT06264973 ·Status: RECRUITING
-
Effects of ACS in Twin With LPB: Study Protocol for a RCT
NCT03547791 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Antenatal Corticosteroid Therapy: Which Impact on Birth Parameters?
NCT05640596 ·Status: COMPLETED
-
The Effect of Antenatal Corticosteroids on the Fetal Thymus - a Possible Role in Fetal Immune Programming
NCT03057717 ·Status: COMPLETED ·Phase: NA
-
Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial)
NCT07098975 ·Status: RECRUITING ·Phase: PHASE2
-
The Effect of Steroids on Maternal Glucose Levels
NCT03021837 ·Status: COMPLETED
-
The Effect Of Antenatal Corticosteroids On Early And Late Perinatal Outcomes
NCT06164080 ·Status: COMPLETED ·Phase: NA
-
Precision Medicine for Preterm Birth
NCT02173210 ·Status: COMPLETED
-
Clinical Pharmacology of Dexamethasone in Pregnant Women With Preterm Labor
NCT05207852 ·Status: RECRUITING
-
Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth
NCT02897076 ·Status: COMPLETED ·Phase: PHASE3
-
Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
NCT01545674 ·Status: TERMINATED
-
Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial (FORECAST)
NCT03941886 ·Status: COMPLETED ·Phase: NA
-
Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
NCT05937841 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor
NCT05742997 ·Status: UNKNOWN ·Phase: NA
-
LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)
NCT04762992 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03674606 ·Status: COMPLETED ·Phase: PHASE4
-
Diagnostic Tests in the Context of Threatened Preterm Labour
NCT03608995 ·Status: COMPLETED ·Phase: NA
-
Metformin to Prevent Preterm Birth in Twin Pregnancy
NCT05412056 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Vascular Effects of High-Salt After Preeclampsia
NCT06749418 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
NCT05934318 ·Status: RECRUITING ·Phase: NA
-
Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth
NCT02092688 ·Status: COMPLETED